Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. [published erratum appears in Arch Ophthalmol 1997 Oct;115(10):1275]. Arch Ophthalmol. 1997 Apr. 115(4):486-91. [Medline].
Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology. 1983 May. 90(5):458-74. [Medline].
Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994 Sep. 42(3):109-32. [Medline].
Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994 Apr 15. 117(4):429-41. [Medline].
Williamson TH. Central retinal vein occlusion: what's the story?. Br J Ophthalmol. 1997 Aug. 81(8):698-704. [Medline].
David R, Zangwill L, Badarna M, et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica. 1988. 197(2):69-74. [Medline].
Ota M, Tsujikawa A, Kita M, et al. Integrity of foveal photoreceptor layer in central retinal vein occlusion. Retina. 2008 Nov-Dec. 28(10):1502-8. [Medline].
Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008 Apr. 126(4):513-8. [Medline].
Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996 Oct. 114(10):1243-7. [Medline].
Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010 Feb. 117 (2):313-9.e1. [Medline].
Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol. 1993 Aug. 111(8):1087-95. [Medline].
Glacet-Bernard A, les Jardins GL, Lasry S, Coscas G, Soubrane G, Souied E, et al. Obstructive sleep apnea among patients with retinal vein occlusion. Arch Ophthalmol. 2010 Dec. 128(12):1533-8. [Medline].
Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008 Feb. 28(1):59-61. [Medline].
Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina. 2005 Oct-Nov. 25(7):846-50. [Medline].
Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995 Oct. 102(10):1425-33. [Medline].
Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol. 2005 Aug. 140(2):200-6. [Medline].
Baxter GM, Williamson TH. Color Doppler flow imaging in central retinal vein occlusion: a new diagnostic technique?. Radiology. 1993 Jun. 187(3):847-50. [Medline].
Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol. 2008 Mar. 116(2):147-52. [Medline].
Gupta B, Grewal J, Adewoyin T, et al. Diurnal variation of macular oedema in CRVO: prospective study. Graefes Arch Clin Exp Ophthalmol. 2008 Dec 4. [Medline].
Chan EW, Eldeeb M, Sun V, Thomas D, Omar A, Kapusta MA, et al. Disorganization of Retinal Inner Layers and Ellipsoid Zone Disruption Predict Visual Outcomes in Central Retinal Vein Occlusion. Ophthalmol Retina. 2019 Jan. 3 (1):83-92. [Medline]. [Full Text].
Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol. 2018 Nov - Dec. 63 (6):816-850. [Medline]. [Full Text].
Kashani AH, Lee SY, Moshfeghi A, Durbin MK, Puliafito CA. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF RETINAL VENOUS OCCLUSION. Retina. 2015 Nov. 35 (11):2323-31. [Medline]. [Full Text].
Khodabandeh A, Shahraki K, Roohipoor R, Riazi-Esfahani H, Yaseri M, Faghihi H, et al. Quantitative measurement of vascular density and flow using optical coherence tomography angiography (OCTA) in patients with central retinal vein occlusion: Can OCTA help in distinguishing ischemic from non-ischemic type?. Int J Retina Vitreous. 2018. 4:47. [Medline]. [Full Text].
Breton ME, Quinn GE, Keene SS, et al. Electroretinogram parameters at presentation as predictors of rubeosis in central retinal vein occlusion patients. Ophthalmology. 1989 Sep. 96(9):1343-52. [Medline].
Sato E, Yamamoto S, Ogata K, et al. Changes of electroretinogram without improvement of retinal circulation after radial optic neurotomy for central retinal vein occlusion. ERG changes after RON for CRVO. Doc Ophthalmol. 2008 Mar. 116(2):153-8. [Medline].
Green WR, Chan CC, Hutchins GM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina. 1981. 1:27-55.
Yeh S, Kim SJ, Ho AC, Schoenberger SD, Bakri SJ, Ehlers JP, et al. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology. Ophthalmology. 2015 Apr. 122 (4):769-78. [Medline]. [Full Text].
Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009 Sep. 127(9):1101-14. [Medline]. [Full Text].
Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC, et al. Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15. JAMA Ophthalmol. 2015 Sep. 133 (9):1022-9. [Medline]. [Full Text].
Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun. 117(6):1134-1146.e3. [Medline].
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun. 117(6):1124-1133.e1. [Medline].
Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol. 2010 Sep. 150(3):310-4. [Medline].
Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J, et al. Improved Vision-Related Function after Ranibizumab for Macular Edema after Retinal Vein Occlusion: Results from the BRAVO and CRUISE Trials. Ophthalmology. 2012 Jul 17. [Medline].
Spaide RF, Chang LK, Klancnik JM, et al. Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion. Am J Ophthalmol. 2008 Oct 17. [Medline].
Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012 Apr. 119 (4):802-9. [Medline]. [Full Text].
Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, et al. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. Ophthalmology. 2016 May. 123 (5):1101-11. [Medline]. [Full Text].
Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012 May. 119(5):1024-32. [Medline].
Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014 Nov. 158 (5):1032-8. [Medline]. [Full Text].
Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014 Jan. 121 (1):202-8. [Medline]. [Full Text].
Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014 Jul. 121 (7):1414-1420.e1. [Medline]. [Full Text].
Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008 Apr. 92(4):518-22. [Medline].
Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology. 2012 Dec. 119 (12):2587-91. [Medline].
Qian T, Zhao M, Wan Y, Li M, Xu X. Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion. BMJ Open. 2018 Dec 28. 8 (12):e022700. [Medline]. [Full Text].
Iftikhar M, Mir TA, Hafiz G, Zimmer-Galler I, Scott AW, Solomon SD, et al. Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema. Am J Ophthalmol. 2019 Apr 4. [Medline]. [Full Text].
Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. 1995 Oct. 102(10):1434-44. [Medline].
Central Vein Occlusion Study Group. Central vein occlusion study of photocoagulation therapy. Baseline findings. Online J Curr Clin Trials. 1993 Oct 14. Doc No 95:[Medline].
Browning DJ, Rotberg MH. Vitreous Hemorrhage complicating laser-induced chorioretinal anastomosis for central retinal vein occlusion. Am J Ophthalmol. 1996 Oct. 122(4):588-9. [Medline].
Eccarius SG, Moran MJ, Slingsby JG. Choroidal neovascular membrane after laser-induced chorioretinal anastomosis. Am J Ophthalmol. 1996 Oct. 122(4):590-1. [Medline].
Luttrull JK. Epiretinal membrane and traction retinal detachment complicating laser- induced chorioretinal venous anastomosis. Am J Ophthalmol. 1997 May. 123(5):698-9. [Medline].
McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. 1995 Apr. 113(4):456-62. [Medline].
Mirshahi A, Roohipoor R, Lashay A, et al. Surgical induction of chorioretinal venous anastomosis in ischaemic central retinal vein occlusion: a non-randomised controlled clinical trial. Br J Ophthalmol. 2005 Jan. 89(1):64-9. [Medline].
Beck AP, Ryan EA, Lou PL, et al. Controversies regarding radial optic neurotomy for central retinal vein occlusion. Int Ophthalmol Clin. 2005 Fall. 45(4):153-61. [Medline].
Binder S, Aggermann T, Brunner S. Long-term effects of radial optic neurotomy for central retinal vein occlusion consecutive interventional case series. Graefes Arch Clin Exp Ophthalmol. 2007 Oct. 245(10):1447-52. [Medline].
Friberg TR, Smolinski P, Hill S, et al. Biomechanical assessment of radial optic neurotomy. Ophthalmology. 2008 Jan. 115(1):174-80. [Medline].
Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina. 2001. 21(5):408-15. [Medline].
Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol. 2003 Nov. 136(5):814-9. [Medline].
Arevalo JF, Garcia RA, Wu L, et al. Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina. 2008 Oct. 28(8):1044-52. [Medline].
Leizaola-Fernandez C, Suarez-Tata L, Quiroz-Mercado H, et al. Vitrectomy with complete posterior hyaloid removal for ischemic central retinal vein occlusion: series of cases. BMC Ophthalmol. 2005 May 20. 5:10. [Medline].
(unpublished) A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety and tolerability of repeated intravitreal administration of VEGF trap-eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) (GALILEO). ClinicalTrials.gov Identifier: NCT01012973.
Bashshur ZF, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004 Aug. 122(8):1137-40. [Medline].
Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004 Aug. 122(8):1131-6. [Medline].
Patel PJ, Zaheer I, Karia N. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye. 2008 Jan. 22(1):60-4. [Medline].
Ramchandran RS, Fekrat S, Stinnett SS, et al. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol. 2008 Aug. 146(2):285-291. [Medline].
Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol. 2007 Dec. 144(6):864-71. [Medline].
Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study. Ophthalmology. 2012 Mar 16. [Medline].
Haller JA, et al. Intravitreal aflibercept injection (IAI) for macular edema secondary to branch retinal vein occlusion (BRVO): 24-week, results of the VIBRANT study. Presented at the 38th annual Macula Society meeting. Scottsdale, AZ. February 21, 2014.